Kpti stock forecast a breakout could attract momentum

A breakout could attract momentum traders, particularly if institutional buying picks up following favorable Phase 2 trial data. In the previous quarter of 2024-06-30, Karyopharm Therapeutics Inc's ( NASDAQ:KPTI ) actual revenue was $42.79 million, which beat analysts' revenue expectations of $36.18 million by 18.26%. Karyopharm Therapeutics Inc's ( NASDAQ:KPTI ) actual earnings were $0.15 per share, which beat analysts' earnings expectations of -$0.30 per share by 150.17%. After releasing the results, Karyopharm Therapeutics Inc ( NASDAQ:KPTI ) was down by -3.56% in one day. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) achieved its third consecutive quarter of net product revenue growth during the third quarter of 2024. The net US XPOVIO revenue sustained its growth from a year ago and posted $29.5 million for Q3. Whereas, the net revenue reached $38.8 million in Q3, up from $36 million from a year ago. The strong commercial performance of XPOVIO has been a key contributor for Karyopharm. Moreover, the company has expanded its reimbursement and regulatory approvals for its lead assets in Italy and France. With further developments of its candidates in ongoing phase three studies, Karyopharm Therapeutics Inc. (KPTI) looks like a solid penny stock to invest in. Market data in the KPTI stock forecast points to RSI levels near 55, suggesting neutral momentum with potential for an upward swing if upcoming trial results beat expectations.